Methods for testing for and handling non-proportional hazards in a phase II rct in chronic lymphocytic leukaemia

被引：0
|
作者：
McParland, Lucy [1 ]
Howard, Dena R. [1 ]
机构：
[1] Univ Leeds, Leeds, W Yorkshire, England
来源：
TRIALS | 2017年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
P448
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings (vol 136, pg 159, 2020)
    Castanon, Eduardo
    Sanchez-Arraez, Alvaro
    Alvarez-Mancenido, Felipe
    Jimenez-Fonseca, Paula
    Carmona-Bayonas, Alberto
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 142 : 152 - 153
  • [22] Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study
    Schey, SA
    Ahsan, G
    Jones, R
    [J]. BONE MARROW TRANSPLANTATION, 1999, 24 (09) : 989 - 993
  • [23] Dose intensification and molecular responses in patients with chronic lymphocytic leukaemia: a phase II single centre study
    SA Schey
    G Ahsan
    R Jones
    [J]. Bone Marrow Transplantation, 1999, 24 : 989 - 993
  • [24] Chronic (mature) lymphoid disorders in adult patients:: chronic lymphocytic leukaemia and leukaemic phase of non-Hodgkin's lymphomas
    Geneviève, F
    Delisle, V
    Gardembas, M
    Foussard, C
    Gardais, J
    Zandecki, M
    [J]. ANNALES DE BIOLOGIE CLINIQUE, 2001, 59 (04) : 403 - 415
  • [25] Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
    Rick A. Vreman
    Joost W. Geenen
    Anke M. Hövels
    Wim G. Goettsch
    Hubert G. M. Leufkens
    Maiwenn J. Al
    [J]. Applied Health Economics and Health Policy, 2019, 17 : 883 - 893
  • [26] Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia
    Vreman, Rick A.
    Geenen, Joost W.
    Hovels, Anke M.
    Goettsch, Wim G.
    Leufkens, Hubert G. M.
    Al, Maiwenn J.
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 883 - 893
  • [27] COSMIC, chemotherapy plus ofatumumab at standard or mega-dose in chronic lymphocytic leukaemia, a phase II randomised study
    Allsup, David
    Howard, Dena
    Emmerson, Jake
    Hockaday, Anna
    Rawstron, Andy
    Oughton, Jamie B.
    Bloor, Adrian
    Phillips, David
    Nathwani, Amit
    Paneesha, Shankara
    Turner, Deborah
    Munir, Talha
    Hillmen, Peter
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 194 (03) : 646 - 650
  • [28] Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia
    Blum, Kristie A.
    Advani, Anjani
    Fernandez, Louis
    Van Der Jagt, Richard
    Brandwein, Joseph
    Kambhampati, Suman
    Kassis, Jeannine
    Davis, Melanie
    Bonfils, Claire
    Dubay, Marja
    Dumouchel, Julie
    Drouin, Michel
    Lucas, David M.
    Martell, Robert E.
    Byrd, John C.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2009, 147 (04) : 507 - 514
  • [29] A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia
    Hillmen, Peter
    Cohen, Dena R.
    Cocks, Kim
    Pettitt, Andrew
    Sayala, Hazem A.
    Rawstron, Andy C.
    Kennedy, Daniel B.
    Fegan, Christopher
    Milligan, Don W.
    Radford, John
    Mercieca, Jane
    Dearden, Claire
    Ezekwisili, Raphael
    Smith, Alexandra F.
    Brown, Julia
    Booth, Gillian A.
    Varghese, Abraham M.
    Pocock, Christopher
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) : 570 - 578
  • [30] Bendamustine plus mitoxantrone -: A new effective treatment for advanced chronic lymphocytic leukaemia:: Results of a phase I/II study
    Köppler, H
    Heymanns, J
    Pandorf, A
    Weide, R
    [J]. LEUKEMIA & LYMPHOMA, 2004, 45 (05) : 911 - 913
12345